Catalent Acquires R.P. Scherer Eberbach
News Mar 02, 2012
Catalent Pharma Solutions has announced that it has completed the acquisition, from Gelita AG, of the remaining 49% minority interest in the R.P. Scherer GmbH & Co. KG, Eberbach, Germany business (“R.P. Scherer Eberbach”).
After 60 years of joint partnership, Catalent and Gelita agreed that the R.P. Scherer Eberbach business will be better able to serve the growing European pharmaceutical and consumer health softgel market with R.P. Scherer fully integrated into Catalent.
Under full Catalent ownership, customers will have access to a wider range of drug development and delivery technologies/services, and a global supply chain network.
R.P. Scherer Corporation (including the Eberbach joint venture) was founded by the inventor of the rotary die production process for softgel capsules and was sold to Cardinal Health PTS, which is now Catalent Pharma Solutions.
Catalent and R.P. Scherer Eberbach have a long heritage of experience, know-how and recognized expertise in softgel formulation and operations.
“We are proud of the strong Catalent and R.P. Scherer Eberbach legacy and are very excited about the future of softgel innovation as an important part of the development, delivery and market supply of pharmaceutical and nutraceutical products. This acquisition comes on the heels of on-going extensive investments that Catalent is making in its softgel facilities in Buenos Aires, Argentina; Aprilia, Italy; and St. Petersburg, Florida; and other investments in advanced drug delivery technologies in Germany and the US,” said David Heyens, President of Catalent’s Softgel Business.
Concept Life Sciences appoints New Group Programme Manager and US Head of SalesNews
Key leadership appointments support integration of the Group and expansion in the US market.READ MORE
Batavia Biosciences Teams Up with International Consortium to Support Polio EradicationNews
Batavia Biosciences announces its partnership with an international consortium coordinated by PATH aiming to develop and manufacture safer novel oral poliovirus vaccines (nOPV).READ MORE
Scientists Cloak Anti-Cancer Drugs in Particles to Target and Destroy Tumor CellsNews
Scientists now report results showing that, by cloaking anti-cancer drugs in a specially designed particle, they could target and destroy tumor cells deep inside a malignant mass in vitro.